Sign in to view Kevin’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
New York, New York, United States
Contact Info
Sign in to view Kevin’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
1K followers
500+ connections
Sign in to view Kevin’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Kevin
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Kevin
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Sign in to view Kevin’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View Kevin’s full profile
Sign in
Stay updated on your professional world
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Explore more posts
-
Benjamin Robinot 💵💡🦾
If you're looking to gain insight into the future of healthcare and biotech innovation, don't miss out on David Khougazian's interview. As an Executive Partner at Flagship Pioneering in Boston, David brings a wealth of experience to the table. In the interview, he discusses his international background, his passion for delivering meaningful differences for patients, and his unique approach to driving innovation in uncharted territories. Check out the full interview to learn more about how David operates "into the wild". 👉link in the comments #biotech #healthcare #innovation #sustainability #Boston
29
1 Comment -
John F. Heerdink, Jr.
Roger Waltzman, Indaptus Therapeutics (NASDAQ: INDP) CMO, explains how they evaluate the effectiveness of #Decoy20. Beyond aiming for a cure, their trials are advancing their understanding of how the immune system works. Their studies rigorously assess tumor response, immune cell responses, survival rates, and quality of life improvements. By analyzing biomarkers, they also identify who might benefit most from their therapies, striving for regulatory approval and global access. Thier mission is to revolutionize #cancertreatment! #IndaptusTherapeutics #CancerResearch #Decoy20 #biotech https://lnkd.in/gYRNhfsK
-
John F. Heerdink, Jr.
Learn more about the innovative "#PulsePrime" approach with Roger Waltzman, Chief Medical Officer at Indaptus Therapeutics (NASDAQ: INDP), as he explains how the novel therapy, Decoy20, is set to revolutionize #cancertreatment. This method involves administering a rapid, potent dose of engineered bacteria directly into the bloodstream—unlike traditional therapies, this "pulse" is brief yet effective enough to activate and prime the #immunesystem without the prolonged exposure that can lead to side effects. This intermittent dosing strategy aims to enhance the immune system's responsiveness and reduce potential adverse reactions, offering new hope to more patients battling advanced cancer. Watch to learn more about how they're harnessing the body's defenses to fight cancer more effectively. https://lnkd.in/gFAVuwMi #IndaptusTherapeutics #CancerResearch #Decoy20 #biotech #ImmunoOncology
-
Steve Kraus
As I said right at the start of this week's The Heart of Healthcare Podcast, Shivdev Rao is one of the most exceptional founders I have ever worked with. He is also a great human being. In this week's episode he shares what is it like leading the 🚀 that is Abridge and some awesome life lessons. IMHO this is a great listen for founders building in both the AI and healthcare fields!
57
3 Comments -
Peter Kolchinsky
If my flight takes off (and lands), looking forward to seeing biotech friends and peers at the Convergence Forum to workshop some ideas for a campaign to save innovation (from mostly misdirected public rage). We'll require only three things to make this possible 1. Read this roadmap article to get in the mood (an outline of the campaign): https://lnkd.in/e8SS-78x 2. Creativity (drinks will help) 3. "Can do" attitude Convergence Forum #biotech No Patient Left Behind
95
5 Comments -
Liam Killingstad
Biotech / HealthTech Roundup J.P. Morgan Biotech Fund JP Morgan Life Sciences closed its inaugural $500M fund to support existing portfolio companies. The fund will focus on biotechs at all stages and therapeutic indications, taking a “hands-on” approach. Fund leader Stephen Squinto stated they aim to make 20-25 investments, primarily in early-stage biotech companies, with investments ranging from $10M to $30M. JP Morgan seeks to be the lead investor, often requiring a board seat or observer role. Europe Regulates Drugs in a New Way A new policy in Europe for assessing drug benefits could limit patient access to treatments like gene therapies. Starting next year, a Joint Clinical Assessment will review a drug's clinical advantages at the European level, potentially undervaluing gene therapies that rely on single-arm trials essential for rare diseases. This could hinder the availability of innovative treatments, exacerbating challenges in bringing new therapies to patients across Europe. Tempus AI IPO AI-based precision medicine company Tempus, founded by Erik Lefkofsky, debuted on the NASDAQ, raising $410.7 million with an implied valuation of $6.1 billion. Backed by Revolution Ventures, Softbank, T. Rowe, and NEA, Tempus has built a large clinical and molecular data library. Initially providing NGS to oncology patients, it now covers neuropsychology, radiology, and cardiology. Tempus generated $532 million in revenue in 2023 but operates at a deficit of $1.5 billion. Pediatric Disease Vouchers Congress faces a deadline to reauthorize a voucher program incentivizing rare pediatric drug development, with concerns over potential abuse. The program, expiring in September, offers priority review vouchers worth $100 million each, potentially advancing older drugs rather than new ones. Despite bipartisan support, the reauthorization faces a challenging congressional schedule ahead of the presidential election, posing a threat to innovation in rare disease research. BIO CEO Looks to Bring Biomanufacturing Back to the US Under new leadership, the Biotechnology Innovation Organization (BIO) is shifting towards US-based biomanufacturing. CEO John Crowley has supported the Biosecure Act, targeting Chinese contractors like WuXi AppTec. This move aims to regain US control over drug manufacturing capabilities. The legislation has raised concerns about high costs and uncertainties for US drug developers relying on Chinese partners. Crowley sees the Act as an opportunity to secure government support for domestic biomanufacturing. Lutetium Shortage Lutetium-177 (Lu-177) faces a potential shortage due to soaring demand, outdated manufacturing infrastructure, and vulnerable supply chains. Lu-177's demand is driven by its role in radiopharmaceutical cancer treatments, with the market expected to reach $7 billion by 2030. Geopolitical tensions and reliance on Russian suppliers further complicate the supply chain. Links to articles in the comments
11
1 Comment -
Patrick Malone, MD PhD
the KdT podcast is back to unpack the first biotech IPO of 2024 - CG Oncology. in The World in a Grain of Sand, we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. in this episode, Cain McClary, MD and Phil Grayeski discuss CG Oncology, and dive into: - the various subtypes of bladder cancer, and one of the most unique standard of care treatment paradigms in oncology, which utilizes a live attenuated virus to treat the disease - supply chain and manufacturing issues that have limited access to SoC therapy in bladder cancer - CG Oncology’s lead (and only) asset, an oncolytic immunotherapy which has delivered impressive complete response data in bladder cancer - challenges and open questions around complex manufacturing, clinical and commercial adoption, and competition for CG’s product - bull vs bear case for the company link to the full episode in the comments.
59
1 Comment -
Vishnu Amble
This one moved fast and demonstrates the sheer prowess of the investment bank's capital markets #distribution access and capabilities to raise capital within existing bank clients across asset and wealth management and investment banking. Congratulations J.P. Morgan Asset Management on raising their inaugural #biotechnology venture capital fund with over $500 million in commitments, attracting strong support from investors including institutional allocators, strategic corporate partners, #familyoffices and high net worth individuals across North America, Europe, the #MiddleEast, and #Asia, as well as JPMorganChase & Co. which can invest a more significant amount from it's balance sheet as part of the 2020 Final Volcker Rule excemption for covered funds, allowing a bank to sponsor a venture capital fund and not be subject to the current 3% limit (or any other limit) on the percentage of such a fund’s ownership interests they can hold, allowing for a more substantial bank balance sheet commitment, often up to 15-20%. The track record of the team is truly remarkable and under J.P. Morgan's leading global healthcare franchise, should have a distinguished advantage in the market for investment and talent sourcing, networks, and liquidity value creation for investors. The Fund invests in private biotechnology companies across stage, modality, therapeutic area, and geography. The Fund's early company formation activities and portfolio investments span cardiometabolic disease, oncology, immunology, and genetic medicines. The #trackrecord of the team is no doubt stellar and we had the opportunity to review in detail and look forward to tracking this progress of this Fund I. #fundraising #alternativeassets #privatemarkets #venturecapital #jpmorgan #capitalmarkets #healthcare #lifesciences #fundmanagers #institutionalinvestors #wealthmanagement https://lnkd.in/ew-sK9b6
12
-
David Haig
The Rise of PIPEs in Biotech: A Financing Revolution Biotech is buzzing with the rise of PIPEs (Private Investment in Public Equity). Adam Feuerstein's recent article reveals the staggering impact of these privately negotiated transactions, which have already raised $4 billion in just the first two months of 2024 across 30 biotech companies. PIPEs involve institutional investors, often hedge funds, purchasing stock directly from public companies, providing much-needed capital without the complexity and delay of traditional public offerings. This trend signifies a crucial shift in biotech financing, enabling rapid infusion of funds to fuel innovation and growth in a highly competitive industry. As the biotech sector continues to evolve, the role of PIPEs in shaping the future landscape cannot be underestimated. For companies navigating this fast-paced environment, leveraging PIPEs could be the key to unlocking new opportunities and staying ahead in the race for breakthrough discoveries. For more insights into this trend, read Adam Feuerstein comprehensive analysis in STAT News: https://lnkd.in/e7TBdfEK #BiotechInnovation #BiotechFinancing #InvestmentTrends #PrivateEquity #CapitalRaising #BiotechGrowth #FinancialStrategies #InstitutionalInvesting #HedgeFundInvestment #BiotechSector #CorporateStrategy #InnovationFunding #StrategicInvestments #biotech
5
-
Pejman Nozad
Our partner Eddie Eltoukhy has identified these opportunities in Biotech. Eddie has a PhD in bioengineering from Massachusetts Institute of Technology and over a decade experience as an operator. Reach out to him if you are working on these areas of biotech. Pear VC - Technology-Driven Therapeutic Platforms Companies developing therapeutic assets with a core product engine Proprietary tool, workflow, or samples leading to novel biological data sets Preference for omics platforms or high throughput screening / engineering workflows First-in-class or best-in-class drugs - Next-Generation Therapeutic Modalities Technologies to improve the efficacy, safety, access, or reach of next-gen modalities including the following: Genomic medicines (gene tx & gene editing) Cell therapies Targeted protein degraders Antibody-drug conjugates Radiopharma - Precision Medicine New technologies supporting the discovery of novel biomarkers and the generation of proprietary data sets for applications in: Disease screening Therapy selection Recurrence monitoring - Life Sciences + AI Software Platforms Software & AI-driven platforms to improve all aspects of life sciences R&D, including: Target discovery and validation Drug design and optimization Manufacturing Regulatory Clinical development
120
5 Comments -
John F. Heerdink, Jr.
We're happy to share some insights from our recent #AACR poster presentation. Our CSO, Michael Newman, and CEO, Jeffrey Meckler, discuss Key findings video from Indaptus Therapeutics (NASDAQ: INDP): "Our poster not only confirmed the robust data from our preclinical animal studies, but also demonstrated similar success with #human #immunecells in the lab. There has been a long-standing misconception that bacteria can only activate the innate side of the immune system—our results clearly show activation of the #adaptive #immunesystem as well. Excitingly, our studies also revealed additive or synergistic effects when combined with the established cancer treatment, Interleukin 2 (IL-2). This suggests additional potential for our Decoy technology in combination therapies. Watch the discussion to learn more about how these findings are fueling our mission to revolutionize cancer treatment. #IndaptusTherapeutics #biotechnology #cancerresearch #Immunotherapy #Decoy20 $INDP #MichaelNewmann #JeffreyMeckler
-
Elan Zivotofsky
Moelis’s deep commitment to the financial sponsor community was reflected in the first quarter of the year, as we provided a range of private equity solutions to sponsors and their businesses. We look forward to continuing this momentum with our clients throughout 2024. Click below to learn more about our recent sponsor transactions. #M&A #Capital Markets #CapitalStructureAdvisory #PrivateFundsAdvisory
14
-
Mark Legare
The opioid crisis was a sad hallmark of my years working for the Baker Administration. In a time of extreme partisanship at the federal level, this was one area where public policy, civil discourse, and private enterprise seemed aligned and sufficiently motivated to find a solution. What we learned, however, is that dollars and access only go so far in combatting a disease that knows no so specific demographic. Instead, it's apparent that a battery of tools is needed to combat and prevent addiction--ranging from strong safety nets, to novel non-addictive pain therapies, and better technology. Introducing Marigold Health. Shrenik Jain, Ravi Shah, Tracey Cohen, MD, FASAM and team have built a proprietary NLP-based platform that--most significantly--improves the lives of those suffering from SUD/SMI. One customer we spoke with noted, "We needed a unique treatment intervention that had supportive research, fit into a CMS established model with a recognized service code, and that would provide positive clinical outcomes in an efficacious and fiscally responsible manner”. Another plainly said: "Marigold is our best hope to reach into the lives and help those who many have already given up on." Honored to join Bill Evans, Sean Day, and the entire syndicate in doing our part to scale a tool we believe will become essential in the fight against addiction. Marigold Health Innospark Ventures Rock Health KdT Ventures Matt Fates Lily Zarrella Venkat Srinivasan
50
1 Comment -
Jonathan Norris
Glad to share my mid year Healthcare Venture report, tracking financing trends in the US and Europe, and sharing perspectives around active investors, valuations, step-ups and exits. Hope you find it valuable! A few interesting details: Fifty $100m+ biopharma investments, twenty-nine including new crossover investors. PE/Growth investors return to lead large deals Dx/Tools, especially in Dx Tests. Med device sees more early-stage investment, particularly in neuro, and multiple new deals by well-known VCs. Healthtech saw increased investment, led by workflow deals in provider ops and clinical trials subsectors and mental/behavioral and women’s health companies in alternative care.
230
15 Comments -
Malikmohamed Yousuf, PhD, MBA, PG-PMP
An investment memo on Laverock Therapeutics. This memo is for research purposes and reflects my interest in writing an investment blog. It should not be considered a recommendation for investment. I have no financial interest or gain from the company discussed, which was selected randomly for my series of memos. I plan to write one or two such memos every month. As this is for personal writing, I do not provide recommendations on investment amounts or deal summaries and hence I have not created exit scenarios analysing different outcomes with multiple probabilities, returns, and the Multiple of Invested Capital (MOIC) as is typical in some investment memos. #investmentmemo #biotech #lifesciences #investment #personalnarrative
5
-
JJ Carrasco
“I’m a strong believer in innovation. I think we have to innovate our way out of the current equation that puts intense demand on capital for biotechs to bring their science to market,” says Jo Varshney. Access to capital is crucial for biotech. Facilitating access through grants, loans, and investment incentives can help biotech startups and small companies secure the funding needed to advance their research and bring products to market. Venture capital firms, angel investors, and government funding programs can provide crucial financial support. This is a helpful read from Willow Shah-Neville. #Innovation #Biotech #Science #Capital #Research #Investing
2
-
Jacqueline Mejia, PhD
Activation Capital is seeking #startups to participate in their NEW Frontier BioHealth program. APPLY NOW! https://lnkd.in/dBiSQuNZ - ❗ Application Deadline: June 17, 2024 - 🏁 Program Kickoff: August 8, 2024 - 🎉 Program End: November 22, 2024 - 💻 Location: All virtual except for three in-person events. Travel costs will be covered! -💰 Investment: We do not invest and we do not take any equity. - 🔬 Startups transitioning #lifesciences innovations from research to commercialization, particularly those originating from academic or federal research labs, are highly encouraged to apply. - 🌟 Startups with a clear commercialization path, some initial funding (dilutive or non-dilutive), a full-time founder, licensing, optioning, or the ability to demonstrate control of their IP are highly encouraged to apply. More About the Program: -Website: https://lnkd.in/dBiSQuNZ -Apply Here: https://lnkd.in/dAFb_XpE -Meet with Jackie to learn more: https://lnkd.in/dF3-Ga3h #medicaldevice #pharma #biotech #diagnostic
40
2 Comments
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More